

002399SZ 09989HK

2020-062

**2020**

--	--	--	--

**1**

			002399SZ 09989HK
		21	21
	0755-26980311		0755-26980311
	stock@hepalink.com		stock@hepalink.com

**2**

	2,659,199,486.98	2,128,873,735.18	24.91%
	581,059,157.84	546,402,001.38	6.34%
	504,563,907.99	65,718,964.64	667.76%
	-245,548,153.21	-183,590,255.09	-33.75%
/	0.4659	0.4381	6.35%
/	0.4659	0.4381	6.35%

	7.70%	8.62%	-0.92%
	16,585,100,612.42	15,242,205,403.45	8.81%
	7,752,504,231.39	7,347,010,761.12	5.52%

## 3

		26,595		0	
10					
		38.01%	474,029,899	0	43,600,000
		32.72%	408,041,280	0	
		3.72%	46,425,600	0	
		3.23%	40,320,000	0	
		1.21%	15,118,035	0	
		0.87%	10,870,036	0	
		0.66%	8,258,825	0	
		0.57%	7,088,166	0	
		0.50%	6,247,987	0	

		0.32%	3,999,008	0	
		38.88%			

**4**

**5**

**10**

**6**

**1**

--	--	--	--	--	--	--

2016

16

112473


2016 11 08

--	--	--	--	--	--	--

2

	52.52%	50.98%	1.54%
EBITDA	7	7.62	-8.14%

1



2020  
1.

2019

37.37%

24.07%

10.49

API

CGMP

1

IMS Health Analytics Link IMS AL) 2019  
6.4%

2017 2017 2000 2019 8000  
323 2019 669  
Prolongin (QCE)

2 API API  
2018 API  
40.7% 2018 50%  
60%  
2. CDMO  
CDMO 3.87  
10.71% 8.04  
SPL CDMO 2018 CDMO CDMO  
CDMO CDMO CDMO  
45 CDMO CMC  
CDMO CDMO  
CDMO III pDNA  
3 pDNA Frost&Sullivan CDMO 24.9%  
2018 15 2024 57 SPL  
pDNA CDMO  
CDMO 24.91%  
667.76%

1.  
2020 7 8 A+H  
H 2020 7 31

2.



CHF RDX-208 2020 1 RDX-208 III MACE  
 2 FDA FDA FDA FDA RDX-208 2020 6 RDX-208  
 FDA FDA FDA FDA  
 III NDA FDA FDA RDX-208 2020 6 RDX-208  
 Oregovomab Resverlogix FDA  
 Oregovomab CA125 OncoQuest  
 38.74% II Oregovomab  
 Oregovomab PFS 41.8 PFS 12.2 (p=0.0027) OS(p=0.0043) PFS  
 OncoQuest III FDA FDA EMA Oregovomab Oregovomab  
 Oregovomab (poly ICLC/Hiltonol) II Ib/IIa Oregovomab  
 PD-1 PARP (niraparib) II Oregovomab  
 2 Kymab (IntelliSelect®) 8.6% Kymab  
 Kymab KY1005 KY1005 IIa  
 KY1005  
 2  
 1  
 2020 1 1 " " 2017 7 5 14 --  
 [2017]22  
 2020 4 29  
 2020 7 8 H  
 " " 2020 < 21 -- > [2018]35  
 2020 8 29  
 2

